AR088793A1 - Compuestos y metodos para mejorar las respuestas inmunitarias innatas - Google Patents
Compuestos y metodos para mejorar las respuestas inmunitarias innatasInfo
- Publication number
- AR088793A1 AR088793A1 ARP120103945A ARP120103945A AR088793A1 AR 088793 A1 AR088793 A1 AR 088793A1 AR P120103945 A ARP120103945 A AR P120103945A AR P120103945 A ARP120103945 A AR P120103945A AR 088793 A1 AR088793 A1 AR 088793A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- halogen
- hydrogen
- nitrile
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Los compuestos se usan para el tratamiento de infecciones virales. Reivindicación 1: Un compuesto que tiene la estructura de acuerdo con la fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde: X¹, X⁴, X⁷, y X⁸ se seleccionan independientemente a partir de N, NH, S, O, C, CH, o CH₂; X² X³, X⁵, y X⁶ se seleccionan independientemente a partir de N, C, o CH; Z se selecciona a partir de un enlace, -C(O), o alquileno C₁₋₆; R¹ se selecciona a partir del grupo que consiste en hidrógeno, -R¹², -R¹⁴, -R⁹(R¹⁵)ₘ, -OR⁹(R¹⁵)ₘ, y halógeno; R² se selecciona a partir del grupo que consiste en hidrógeno, alquilo C₁₋₆, alcoxilo C₁₋₆, -R¹², -R¹⁴, C(O)R¹², -R⁹R¹², -R⁹R¹³, -R⁹R¹⁴, -C(O)R¹⁴, -R⁹(R¹⁵)ₘ, -OR⁹(R¹⁵)ₘ, -OR¹³, -R¹²S(O)₂, -S(O)₂R¹², halógeno, nitrilo, sulfonamida, sulfona, sulfóxido, arilo C₄₋₁₄, y cicloalquilo C₃₋₁₂, en donde el grupo R² puede estar opcionalmente sustituido con uno a tres grupos R¹¹; R³ se selecciona a partir del grupo que consiste en hidrógeno, alquilo C₁₋₆, alcoxilo C₁₋₆, -R¹², -R¹⁴, C(O)R¹², -R⁹R¹², -R⁹R¹³, -R⁹R¹⁴, -C(O)R¹⁴, -R⁹(R¹⁵)ₘ, -OR⁹(R¹⁵)ₘ, -OR¹³, halógeno, nitrilo, sulfonamida, sulfona, sulfóxido, arilo C₄₋₁₄, y cicloalquilo C₃₋₁₂, en donde el grupo R³ puede estar opcionalmente sustituido con uno a tres grupos R¹¹; R⁴ está opcionalmente ausente o se selecciona a partir que consiste en hidrógeno, alquilo C₁₋₆, -R⁹(R¹⁵)ₘ, -OR⁹(R¹⁵)ₘ, -R⁹R¹⁰, -C(O)R⁹, -C(O)R¹³, halógeno, y cicloalquilo C₃₋₁₂; R⁵ se selecciona a partir del grupo que hidrógeno, alquilo C₁₋₆, -C(O)R¹², -R⁹R¹², -R⁹(R¹⁵)ₘ, -OR⁹(R¹⁵)ₘ, -R¹⁴, halógeno, y nitrilo; R⁶ se selecciona a partir del grupo que consiste en hidrógeno, alquilo C₁₋₆, alcoxilo C₁₋₆, -R¹², -R¹⁴, C(O)R¹², -R⁹R¹², -R⁹R¹³, -R⁹R¹⁴, -C(O)R¹⁴, -R⁹(R¹⁵)ₘ, -OR⁹(R¹⁵)ₘ, -OR¹³, halógeno, nitrilo, sulfonamida, sulfona, sulfóxido, arilo C₄₋₁₄, y cicloalquilo C₃₋₁₂, en donde el grupo R⁶ puede estar opcionalmente sustituido con uno a tres grupos R¹¹; R⁷ se selecciona a partir del grupo que consiste en hidrógeno, alquilo C₁₋₆, -R⁹(R¹⁵)ₘ, -OR⁹(R¹⁵)ₘ, halógeno, -C(O)R¹², -R⁹R¹², nitrilo, y -R¹⁴; R⁸ se selecciona independientemente a partir del grupo que consiste en hidrógeno y alquilo C₁₋₆; R⁹ es alquilo C₁₋₆; R¹⁰ es arilo C₄₋₁₄; R¹¹ se selecciona a partir del grupo que consiste en alquilo C₁₋₆, dimetilo, sulfonamida, -OR⁸, -C(O)R¹², oxo, nitrilo, -R¹², halógeno, -R⁹(R¹⁵)ₘ, y -OR⁹(R¹⁵)ₘ; R¹² es -NRˣRʸ, en donde Rˣ y Rʸ se seleccionan independientemente a partir del grupo que consiste en hidrógeno y alquilo C₁₋₆; en donde Rˣ y Rʸ se pueden unir opcionalmente entre sí, junto con el nitrógeno con el que están unidos, para formar un anillo heterocíclico C₁₋₁₁ o un anillo de heteroarilo C₁₋₁₁, en donde el anillo heterocíclico o el anillo de heteroarilo independientemente tienen de uno a cuatro heteroátomos seleccionados a partir de N, S y O, y en donde el anillo heterocíclico o el anillo de heteroarilo pueden estar también opcionalmente sustituidos con uno a tres grupos R¹¹; R¹³ es cicloalquilo C₃₋₁₂; R¹⁴ se selecciona a partir del grupo que consiste en heteroarilo C₁₋₁₁ o heterocíclico C₁₋₁₁, en donde el heterocíclico C₁₋₁₁ o el heteroarilo C₁₋₁₁ cada uno puede tener de uno a tres heteroátomos seleccionados a partir de N, S, u O, y en donde el heteroarilo C₁₋₁₁ o el heterocíclico C₁₋₁₁ también pueden estar opcionalmente sustituidos por uno a tres grupos R¹¹ independientes; R¹⁵ es halógeno; y m es independientemente 0 o un entero de 1 a 3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549784P | 2011-10-21 | 2011-10-21 | |
| US201261692431P | 2012-08-23 | 2012-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088793A1 true AR088793A1 (es) | 2014-07-10 |
Family
ID=48141628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103945A AR088793A1 (es) | 2011-10-21 | 2012-10-22 | Compuestos y metodos para mejorar las respuestas inmunitarias innatas |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20140249143A1 (es) |
| EP (1) | EP2768506A4 (es) |
| JP (1) | JP2014532626A (es) |
| KR (1) | KR20140094559A (es) |
| CN (1) | CN103957910A (es) |
| AR (1) | AR088793A1 (es) |
| AU (1) | AU2012325971B2 (es) |
| BR (1) | BR112014008727A2 (es) |
| CA (1) | CA2851801A1 (es) |
| CL (1) | CL2014001016A1 (es) |
| CO (1) | CO6910198A2 (es) |
| CR (1) | CR20140175A (es) |
| DO (1) | DOP2014000081A (es) |
| EA (1) | EA201490610A1 (es) |
| IL (1) | IL231894A0 (es) |
| MX (1) | MX2014004814A (es) |
| PE (1) | PE20141359A1 (es) |
| SG (2) | SG11201400988SA (es) |
| TW (2) | TW201333003A (es) |
| UY (1) | UY34406A (es) |
| WO (1) | WO2013059559A2 (es) |
| ZA (1) | ZA201402392B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103333168B (zh) * | 2013-07-23 | 2015-08-05 | 清华大学 | 一种酰胺类化合物及其制备方法与应用 |
| US9758518B2 (en) | 2015-03-04 | 2017-09-12 | Pimera, Inc. | Compositions, uses and methods for making them |
| WO2016053893A1 (en) * | 2014-09-29 | 2016-04-07 | The Trustees Of The University Of Pennsylvania | Antivirals against molluscum contagiosum virus |
| CN104529893B (zh) * | 2014-12-30 | 2016-08-24 | 中国科学技术大学 | 一类可以作为高尔基体细胞器探针的喹啉染料 |
| CN105175277B (zh) * | 2015-05-18 | 2018-04-03 | 中山大学肿瘤防治中心 | 一种3‑磷酸甘油醛脱氢酶的抑制剂及其制备方法和应用 |
| WO2018043747A1 (ja) * | 2016-09-05 | 2018-03-08 | 国立大学法人京都大学 | 抗ｂ型肝炎ウイルス剤 |
| WO2018183540A1 (en) | 2017-03-28 | 2018-10-04 | Pimera, Inc. | Novel crystal forms of a pol1 inhibitor |
| BR112021006121A2 (pt) | 2018-10-23 | 2021-07-20 | Basf Se | compostos, uso dos compostos de fórmula (i), mistura de pesticidas, composições agroquímicas ou veterinárias, métodos para controlar pragas invertebradas e para tratar ou proteger animais e semente |
| CN114732823B (zh) * | 2019-03-13 | 2023-05-23 | 中国人民解放军军事科学院军事医学研究院 | 氨基葡萄糖及其衍生物作为抗病毒药物的应用 |
| WO2021209265A1 (en) | 2020-04-14 | 2021-10-21 | Basf Se | Tricyclic pesticidal compounds |
| EP4208166A1 (en) * | 2020-09-03 | 2023-07-12 | GlaxoSmithKline Intellectual Property Development Ltd | Imidazonaphthyridines and imidazopyridopyrimidines as ifnar2 agonists for treating sars-cov-2 infections |
| WO2022175425A1 (en) | 2021-02-22 | 2022-08-25 | Glaxosmithkline Intellectual Property Development Limited | Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection |
| WO2023064857A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
| WO2023244672A1 (en) | 2022-06-14 | 2023-12-21 | Assembly Biosciences, Inc. | 2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL59104A (en) * | 1979-02-09 | 1984-02-29 | Roussel Uclaf | Heterotricyclic derivatives,process for their preparation and pharmaceutical compositions incorporating them |
| US4492697A (en) * | 1983-08-16 | 1985-01-08 | Ayerst, Mckenna & Harrison, Inc. | 4H-Imidazo[2,3-c]pyrido[2,3-e][1,4]oxazine derivatives |
| US6110929A (en) * | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| JP2006503802A (ja) * | 2002-04-03 | 2006-02-02 | エフ．ホフマン−ラ ロシュ アーゲー | イミダゾ縮合化合物 |
| US8592368B2 (en) * | 2003-12-19 | 2013-11-26 | University Of South Florida | JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection |
| DE102005019181A1 (de) * | 2005-04-25 | 2006-10-26 | Novartis Ag | Peptid-Deformylase (PDF) Inhibitoren 1 |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| WO2010113416A1 (ja) * | 2009-03-31 | 2010-10-07 | ダイキン工業株式会社 | 高分子アクチュエータ素子用電極膜及びそれを有する高分子アクチュエータ素子 |
| GB0919432D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB201002409D0 (en) * | 2010-02-12 | 2010-03-31 | Univ Nottingham | Methods |
-
2012
- 2012-10-19 AU AU2012325971A patent/AU2012325971B2/en not_active Ceased
- 2012-10-19 EA EA201490610A patent/EA201490610A1/ru unknown
- 2012-10-19 US US14/353,067 patent/US20140249143A1/en not_active Abandoned
- 2012-10-19 EP EP12840986.9A patent/EP2768506A4/en not_active Withdrawn
- 2012-10-19 CA CA2851801A patent/CA2851801A1/en not_active Abandoned
- 2012-10-19 PE PE2014000559A patent/PE20141359A1/es not_active Application Discontinuation
- 2012-10-19 JP JP2014537274A patent/JP2014532626A/ja active Pending
- 2012-10-19 SG SG11201400988SA patent/SG11201400988SA/en unknown
- 2012-10-19 CN CN201280051347.8A patent/CN103957910A/zh active Pending
- 2012-10-19 KR KR1020147013668A patent/KR20140094559A/ko not_active Application Discontinuation
- 2012-10-19 SG SG10201505664WA patent/SG10201505664WA/en unknown
- 2012-10-19 WO PCT/US2012/060971 patent/WO2013059559A2/en active Application Filing
- 2012-10-19 MX MX2014004814A patent/MX2014004814A/es unknown
- 2012-10-19 BR BR112014008727A patent/BR112014008727A2/pt not_active IP Right Cessation
- 2012-10-22 AR ARP120103945A patent/AR088793A1/es unknown
- 2012-10-22 UY UY0001034406A patent/UY34406A/es not_active Application Discontinuation
- 2012-10-22 TW TW101138997A patent/TW201333003A/zh unknown
- 2012-10-22 TW TW104126180A patent/TW201542567A/zh unknown
-
2014
- 2014-03-18 CO CO14058151A patent/CO6910198A2/es unknown
- 2014-03-31 ZA ZA2014/02392A patent/ZA201402392B/en unknown
- 2014-04-03 IL IL231894A patent/IL231894A0/en unknown
- 2014-04-21 DO DO2014000081A patent/DOP2014000081A/es unknown
- 2014-04-21 CR CR20140175A patent/CR20140175A/es unknown
- 2014-04-21 CL CL2014001016A patent/CL2014001016A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140249143A1 (en) | 2014-09-04 |
| MX2014004814A (es) | 2014-05-27 |
| KR20140094559A (ko) | 2014-07-30 |
| SG11201400988SA (en) | 2014-07-30 |
| DOP2014000081A (es) | 2014-07-15 |
| AU2012325971A1 (en) | 2014-04-17 |
| EA201490610A1 (ru) | 2014-09-30 |
| ZA201402392B (en) | 2017-09-27 |
| JP2014532626A (ja) | 2014-12-08 |
| WO2013059559A2 (en) | 2013-04-25 |
| EP2768506A2 (en) | 2014-08-27 |
| TW201333003A (zh) | 2013-08-16 |
| IL231894A0 (en) | 2014-05-28 |
| TW201542567A (zh) | 2015-11-16 |
| BR112014008727A2 (pt) | 2017-04-25 |
| CL2014001016A1 (es) | 2015-01-16 |
| WO2013059559A3 (en) | 2013-11-14 |
| CR20140175A (es) | 2014-06-03 |
| CN103957910A (zh) | 2014-07-30 |
| PE20141359A1 (es) | 2014-10-13 |
| AU2012325971B2 (en) | 2016-03-31 |
| SG10201505664WA (en) | 2015-09-29 |
| EP2768506A4 (en) | 2015-08-19 |
| CA2851801A1 (en) | 2013-04-25 |
| UY34406A (es) | 2013-05-31 |
| CO6910198A2 (es) | 2014-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088793A1 (es) | Compuestos y metodos para mejorar las respuestas inmunitarias innatas | |
| AR095464A1 (es) | Compuestos de heteroarilo y usos de los mismos | |
| AR092959A1 (es) | Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| AR094313A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR110922A1 (es) | Compuestos inhibidores del vih | |
| AR117616A1 (es) | Compuestos anti-vih | |
| AR102492A1 (es) | Cromanos sustituidos y métodos para su uso | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR092522A1 (es) | Inhibidores de glucosilceramida sintasa | |
| AR093036A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| AR092348A1 (es) | DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc | |
| AR106595A1 (es) | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR104362A1 (es) | Dihidropiridoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios | |
| AR106865A1 (es) | Piridinas sustituidas y métodos de uso | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| ES2620668T3 (es) | Derivados de amidas y sulfonamidas amido espirocíclicas | |
| AR097571A1 (es) | Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR112290A1 (es) | Dinucleótidos cíclicos como agentes anticáncer | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR078609A1 (es) | 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros. | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |